ID   BCL6_HUMAN              Reviewed;         706 AA.
AC   P41182; A7E241; B8PSA7; D3DNV5;
DT   01-FEB-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1995, sequence version 1.
DT   28-JUN-2023, entry version 229.
DE   RecName: Full=B-cell lymphoma 6 protein;
DE            Short=BCL-6;
DE   AltName: Full=B-cell lymphoma 5 protein;
DE            Short=BCL-5;
DE   AltName: Full=Protein LAZ-3;
DE   AltName: Full=Zinc finger and BTB domain-containing protein 27;
DE   AltName: Full=Zinc finger protein 51;
GN   Name=BCL6; Synonyms=BCL5, LAZ3, ZBTB27, ZNF51;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Skeletal muscle;
RX   PubMed=8220427; DOI=10.1038/ng0993-66;
RA   Kerckaert J.-P., Deweindt C., Tilly H., Quief S., Lecocq G., Bastard C.;
RT   "LAZ3, a novel zinc-finger encoding gene, is disrupted by recurring
RT   chromosome 3q27 translocations in human lymphomas.";
RL   Nat. Genet. 5:66-70(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=8235596; DOI=10.1126/science.8235596;
RA   Ye B.H., Lista F., Lo Coco F., Knowles D.M., Offit K., Chaganti R.S.K.,
RA   Dalla-Favera R.;
RT   "Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell
RT   lymphoma.";
RL   Science 262:747-750(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=8274740;
RA   Miki T., Kawamata N., Hirosawa S., Aoki N.;
RT   "Gene involved in the 3q27 translocation associated with B-cell lymphoma,
RT   BCL5, encodes a Kruppel-like zinc-finger protein.";
RL   Blood 83:26-32(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=8506375; DOI=10.1073/pnas.90.11.5262;
RA   Baron B.W., Nucifora G., McCabe N., Espinosa R. III, le Beau M.M.,
RA   McKeithan T.W.;
RT   "Identification of the gene associated with the recurring chromosomal
RT   translocations t(3;14)(q27;q32) and t(3;22)(q27;q11) in B-cell lymphomas.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:5262-5266(1993).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RA   Mao Y., Xiao X., He D., Luo C., Liu C., Lv D.;
RT   "Discovery of a novel BCL6 transcript and its expression in lung cancer.";
RL   Submitted (SEP-2007) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J.,
RA   Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P.,
RA   Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A.,
RA   Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G.,
RA   Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W.,
RA   Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M.,
RA   Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P.,
RA   Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H.,
RA   Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J.,
RA   Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W.,
RA   Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B.,
RA   Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O.,
RA   Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X.,
RA   Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R.,
RA   Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   FUNCTION, TISSUE SPECIFICITY, PHOSPHORYLATION AT SER-333 AND SER-343,
RP   MUTAGENESIS OF SER-333 AND SER-343, AND UBIQUITINATION.
RX   PubMed=9649500; DOI=10.1101/gad.12.13.1953;
RA   Niu H., Ye B.H., Dalla-Favera R.;
RT   "Antigen receptor signaling induces MAP kinase-mediated phosphorylation and
RT   degradation of the BCL-6 transcription factor.";
RL   Genes Dev. 12:1953-1961(1998).
RN   [10]
RP   INVOLVEMENT IN B-CELL NON-HODGKIN LYMPHOMA, AND CHROMOSOMAL TRANSLOCATION
RP   WITH LCP1.
RX   PubMed=10469447;
RX   DOI=10.1002/(sici)1098-2264(199910)26:2<97::aid-gcc1>3.3.co;2-0;
RA   Galiegue-Zouitina S., Quief S., Hildebrand M.P., Denis C.,
RA   Detourmignies L., Lai J.L., Kerckaert J.P.;
RT   "Nonrandom fusion of L-plastin(LCP1) and LAZ3(BCL6) genes by
RT   t(3;13)(q27;q14) chromosome translocation in two cases of B-cell non-
RT   Hodgkin lymphoma.";
RL   Genes Chromosomes Cancer 26:97-105(1999).
RN   [11]
RP   INVOLVEMENT IN B-CELL NON-HODGKIN LYMPHOMA, AND CHROMOSOMAL TRANSLOCATION
RP   WITH IKZF1.
RX   PubMed=10753856;
RA   Hosokawa Y., Maeda Y., Ichinohasama R., Miura I., Taniwaki M., Seto M.;
RT   "The Ikaros gene, a central regulator of lymphoid differentiation, fuses to
RT   the BCL6 gene as a result of t(3;7)(q27;p12) translocation in a patient
RT   with diffuse large B-cell lymphoma.";
RL   Blood 95:2719-2721(2000).
RN   [12]
RP   FUNCTION AS TRANSCRIPTIONAL REPRESSOR, AND TISSUE SPECIFICITY.
RX   PubMed=10981963; DOI=10.1016/s1074-7613(00)00020-0;
RA   Shaffer A.L., Yu X., He Y., Boldrick J., Chan E.P., Staudt L.M.;
RT   "BCL-6 represses genes that function in lymphocyte differentiation,
RT   inflammation, and cell cycle control.";
RL   Immunity 13:199-212(2000).
RN   [13]
RP   FUNCTION AS TRANSCRIPTIONAL REPRESSOR, INVOLVEMENT IN B-CELL NON-HODGKIN
RP   LYMPHOMA, AND CHROMOSOMAL TRANSLOCATION WITH HISTONE H4.
RX   PubMed=12414651;
RA   Kurata M., Maesako Y., Ueda C., Nishikori M., Akasaka T., Uchiyama T.,
RA   Ohno H.;
RT   "Characterization of t(3;6)(q27;p21) breakpoints in B-cell non-Hodgkin's
RT   lymphoma and construction of the histone H4/BCL6 fusion gene, leading to
RT   altered expression of Bcl-6.";
RL   Cancer Res. 62:6224-6230(2002).
RN   [14]
RP   FUNCTION AS TRANSCRIPTIONAL REPRESSOR, ACETYLATION AT LYS-379,
RP   DEACETYLATION, INTERACTION WITH HDAC2, TISSUE SPECIFICITY, AND MUTAGENESIS
RP   OF LYS-376; LYS-377 AND LYS-379.
RX   PubMed=12402037; DOI=10.1038/ng1018;
RA   Bereshchenko O.R., Gu W., Dalla-Favera R.;
RT   "Acetylation inactivates the transcriptional repressor BCL6.";
RL   Nat. Genet. 32:606-613(2002).
RN   [15]
RP   INVOLVEMENT IN B-CELL NON-HODGKIN LYMPHOMA, AND CHROMOSOMAL TRANSLOCATION
RP   WITH IL21R.
RX   PubMed=11821949; DOI=10.1038/sj.onc.1205099;
RA   Ueda C., Akasaka T., Kurata M., Maesako Y., Nishikori M., Ichinohasama R.,
RA   Imada K., Uchiyama T., Ohno H.;
RT   "The gene for interleukin-21 receptor is the partner of BCL6 in
RT   t(3;16)(q27;p11), which is recurrently observed in diffuse large B-cell
RT   lymphoma.";
RL   Oncogene 21:368-376(2002).
RN   [16]
RP   FUNCTION AS TRANSCRIPTIONAL REPRESSOR, DNA-BINDING, SUBCELLULAR LOCATION,
RP   INTERACTION WITH HDAC5, AND MUTAGENESIS OF 520-CYS--CYS-523;
RP   548-CYS--CYS-551; 576-CYS--CYS-579; 604-CYS--CYS-607; 632-CYS--CYS-635 AND
RP   660-CYS--CYS-663.
RX   PubMed=12504096; DOI=10.1016/s0006-291x(02)02873-5;
RA   Mascle X., Albagli O., Lemercier C.;
RT   "Point mutations in BCL6 DNA-binding domain reveal distinct roles for the
RT   six zinc fingers.";
RL   Biochem. Biophys. Res. Commun. 300:391-396(2003).
RN   [17]
RP   INTERACTION WITH HDAC9.
RX   PubMed=12590135; DOI=10.1074/jbc.m212935200;
RA   Petrie K., Guidez F., Howell L., Healy L., Waxman S., Greaves M.,
RA   Zelent A.;
RT   "The histone deacetylase 9 gene encodes multiple protein isoforms.";
RL   J. Biol. Chem. 278:16059-16072(2003).
RN   [18]
RP   FUNCTION IN B-CELL DIFFERENTIATION, INTERACTION WITH NCOR1; NCOR2 AND NURD
RP   COMPLEX, ACETYLATION, TISSUE SPECIFICITY, AND MUTAGENESIS OF LYS-379 AND
RP   376-LYS--LYS-379.
RX   PubMed=15454082; DOI=10.1016/j.cell.2004.09.014;
RA   Fujita N., Jaye D.L., Geigerman C., Akyildiz A., Mooney M.R., Boss J.M.,
RA   Wade P.A.;
RT   "MTA3 and the Mi-2/NuRD complex regulate cell fate during B lymphocyte
RT   differentiation.";
RL   Cell 119:75-86(2004).
RN   [19]
RP   FUNCTION AS TP53 TRANSCRIPTIONAL REPRESSOR.
RX   PubMed=15577913; DOI=10.1038/nature03147;
RA   Phan R.T., Dalla-Favera R.;
RT   "The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B-
RT   cells.";
RL   Nature 432:635-639(2004).
RN   [20]
RP   FUNCTION AS TRANSCRIPTIONAL REPRESSOR, INTERACTION WITH ZBTB17, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=16142238; DOI=10.1038/ni1245;
RA   Phan R.T., Saito M., Basso K., Niu H., Dalla-Favera R.;
RT   "BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-
RT   dependent kinase inhibitor p21 and cell cycle arrest in germinal center B
RT   cells.";
RL   Nat. Immunol. 6:1054-1060(2005).
RN   [21]
RP   INDUCTION, AND TISSUE SPECIFICITY.
RX   PubMed=16455075; DOI=10.1016/j.yexcr.2005.12.020;
RA   Pantano S., Jarrossay D., Saccani S., Bosisio D., Natoli G.;
RT   "Plastic downregulation of the transcriptional repressor BCL6 during
RT   maturation of human dendritic cells.";
RL   Exp. Cell Res. 312:1312-1322(2006).
RN   [22]
RP   FUNCTION, PHOSPHORYLATION BY ATM, INDUCTION BY GENOTOXIC STRESS,
RP   INTERACTION WITH PIN1, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND
RP   MUTAGENESIS OF THR-190; SER-250 AND SER-260.
RX   PubMed=17828269; DOI=10.1038/ni1508;
RA   Phan R.T., Saito M., Kitagawa Y., Means A.R., Dalla-Favera R.;
RT   "Genotoxic stress regulates expression of the proto-oncogene Bcl6 in
RT   germinal center B cells.";
RL   Nat. Immunol. 8:1132-1139(2007).
RN   [23]
RP   FUNCTION AS AUTOINHIBITOR, INTERACTION WITH CTBP1; HDAC2 AND NCOR2, TISSUE
RP   SPECIFICITY, AND MUTAGENESIS OF ASN-21; HIS-116 AND 376-LYS--LYS-379.
RX   PubMed=18212045; DOI=10.1128/mcb.01400-07;
RA   Mendez L.M., Polo J.M., Yu J.J., Krupski M., Ding B.B., Melnick A.,
RA   Ye B.H.;
RT   "CtBP is an essential corepressor for BCL6 autoregulation.";
RL   Mol. Cell. Biol. 28:2175-2186(2008).
RN   [24]
RP   FUNCTION IN MIRNA REGULATION, AND SUBCELLULAR LOCATION.
RX   PubMed=23166356; DOI=10.1084/jem.20121387;
RA   Basso K., Schneider C., Shen Q., Holmes A.B., Setty M., Leslie C.,
RA   Dalla-Favera R.;
RT   "BCL6 positively regulates AID and germinal center gene expression via
RT   repression of miR-155.";
RL   J. Exp. Med. 209:2455-2465(2012).
RN   [25]
RP   FUNCTION, INTERACTION WITH SCF(FBXO11) COMPLEX, UBIQUITINATION,
RP   PHOSPHORYLATION, AND SUBCELLULAR LOCATION.
RX   PubMed=22113614; DOI=10.1038/nature10688;
RA   Duan S., Cermak L., Pagan J.K., Rossi M., Martinengo C., di Celle P.F.,
RA   Chapuy B., Shipp M., Chiarle R., Pagano M.;
RT   "FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-
RT   cell lymphomas.";
RL   Nature 481:90-93(2012).
RN   [26]
RP   FUNCTION AS TRANSCRIPTIONAL REPRESSOR, INTERACTION WITH BCOR; HDAC3; NCOR1
RP   AND NCOR2, AND DNA-BINDING.
RX   PubMed=23911289; DOI=10.1016/j.celrep.2013.06.016;
RA   Hatzi K., Jiang Y., Huang C., Garrett-Bakelman F., Gearhart M.D.,
RA   Giannopoulou E.G., Zumbo P., Kirouac K., Bhaskara S., Polo J.M.,
RA   Kormaksson M., Mackerell A.D. Jr., Xue F., Mason C.E., Hiebert S.W.,
RA   Prive G.G., Cerchietti L., Bardwell V.J., Elemento O., Melnick A.;
RT   "A hybrid mechanism of action for BCL6 in B cells defined by formation of
RT   functionally distinct complexes at enhancers and promoters.";
RL   Cell Rep. 4:578-588(2013).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-333, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [28]
RP   UBIQUITINATION, AND MUTAGENESIS OF SER-59.
RX   PubMed=30190310; DOI=10.1126/science.aap8236;
RA   Mena E.L., Kjolby R.A.S., Saxton R.A., Werner A., Lew B.G., Boyle J.M.,
RA   Harland R., Rape M.;
RT   "Dimerization quality control ensures neuronal development and survival.";
RL   Science 362:eaap8236-eaap8236(2018).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 5-129 IN COMPLEX WITH NCOR2.
RX   PubMed=14690607; DOI=10.1016/s1097-2765(03)00454-4;
RA   Ahmad K.F., Melnick A., Lax S., Bouchard D., Liu J., Kiang C.L., Mayer S.,
RA   Takahashi S., Licht J.D., Prive G.G.;
RT   "Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain.";
RL   Mol. Cell 12:1551-1564(2003).
RN   [30]
RP   STRUCTURE BY NMR OF 598-657.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the C2H2 type zinc finger (region 598-654) of human
RT   B-cell lymphoma 6 protein.";
RL   Submitted (OCT-2007) to the PDB data bank.
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 5-129.
RX   PubMed=19052359; DOI=10.1107/s1744309108036063;
RA   Stead M.A., Rosbrook G.O., Hadden J.M., Trinh C.H., Carr S.B., Wright S.C.;
RT   "Structure of the wild-type human BCL6 POZ domain.";
RL   Acta Crystallogr. F 64:1101-1104(2008).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 5-129 IN COMPLEX WITH BCOR,
RP   FUNCTION, AND SUBUNIT.
RX   PubMed=18280243; DOI=10.1016/j.molcel.2007.12.026;
RA   Ghetu A.F., Corcoran C.M., Cerchietti L., Bardwell V.J., Melnick A.,
RA   Prive G.G.;
RT   "Structure of a BCOR corepressor peptide in complex with the BCL6 BTB
RT   domain dimer.";
RL   Mol. Cell 29:384-391(2008).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 5-129 IN COMPLEX WITH INHIBITOR.
RX   PubMed=20385364; DOI=10.1016/j.ccr.2009.12.050;
RA   Cerchietti L.C., Ghetu A.F., Zhu X., Da Silva G.F., Zhong S., Matthews M.,
RA   Bunting K.L., Polo J.M., Fares C., Arrowsmith C.H., Yang S.N., Garcia M.,
RA   Coop A., Mackerell A.D. Jr., Prive G.G., Melnick A.;
RT   "A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in
RT   vivo.";
RL   Cancer Cell 17:400-411(2010).
CC   -!- FUNCTION: Transcriptional repressor mainly required for germinal center
CC       (GC) formation and antibody affinity maturation which has different
CC       mechanisms of action specific to the lineage and biological functions.
CC       Forms complexes with different corepressors and histone deacetylases to
CC       repress the transcriptional expression of different subsets of target
CC       genes. Represses its target genes by binding directly to the DNA
CC       sequence 5'-TTCCTAGAA-3' (BCL6-binding site) or indirectly by
CC       repressing the transcriptional activity of transcription factors. In GC
CC       B-cells, represses genes that function in differentiation,
CC       inflammation, apoptosis and cell cycle control, also autoregulates its
CC       transcriptional expression and up-regulates, indirectly, the expression
CC       of some genes important for GC reactions, such as AICDA, through the
CC       repression of microRNAs expression, like miR155. An important function
CC       is to allow GC B-cells to proliferate very rapidly in response to T-
CC       cell dependent antigens and tolerate the physiological DNA breaks
CC       required for immunglobulin class switch recombination and somatic
CC       hypermutation without inducing a p53/TP53-dependent apoptotic response.
CC       In follicular helper CD4(+) T-cells (T(FH) cells), promotes the
CC       expression of T(FH)-related genes but inhibits the differentiation of
CC       T(H)1, T(H)2 and T(H)17 cells. Also required for the establishment and
CC       maintenance of immunological memory for both T- and B-cells. Suppresses
CC       macrophage proliferation through competition with STAT5 for STAT-
CC       binding motifs binding on certain target genes, such as CCL2 and CCND2.
CC       In response to genotoxic stress, controls cell cycle arrest in GC B-
CC       cells in both p53/TP53-dependedent and -independent manners. Besides,
CC       also controls neurogenesis through the alteration of the composition of
CC       NOTCH-dependent transcriptional complexes at selective NOTCH targets,
CC       such as HES5, including the recruitment of the deacetylase SIRT1 and
CC       resulting in an epigenetic silencing leading to neuronal
CC       differentiation. {ECO:0000269|PubMed:10981963,
CC       ECO:0000269|PubMed:12402037, ECO:0000269|PubMed:12414651,
CC       ECO:0000269|PubMed:12504096, ECO:0000269|PubMed:15454082,
CC       ECO:0000269|PubMed:15577913, ECO:0000269|PubMed:16142238,
CC       ECO:0000269|PubMed:17828269, ECO:0000269|PubMed:18212045,
CC       ECO:0000269|PubMed:18280243, ECO:0000269|PubMed:22113614,
CC       ECO:0000269|PubMed:23166356, ECO:0000269|PubMed:23911289,
CC       ECO:0000269|PubMed:9649500}.
CC   -!- SUBUNIT: Homodimer. Interacts (via BTB domain) with the corepressors
CC       BCOR, NCOR1 and SMRT/NCOR2; the interactions are direct. Forms
CC       preferably ternary complexes with BCOR and SMRT/NCOR2 on target gene
CC       promoters but, on enhancer elements, interacts with SMRT/NCOR2 and
CC       HDAC3 to repress proximal gene expression. Interacts with histone
CC       deacetylases HDAC2, HDAC5 and HDAC9 (via the catalytic domain).
CC       Interacts with ZBTB7 and BCL6B. Interacts with SCF(FBXO11) complex; the
CC       interaction is independent of phosphorylation and promotes
CC       ubiquitination. Interacts (when phosphorylated) with PIN1; the
CC       interaction is required for BCL6 degradation upon genotoxic stress.
CC       Interacts with ZBTB17; inhibits ZBTB17 transcriptional activity.
CC       Interacts with CTBP1, autoinhibits its transcriptional expression.
CC       Interacts with NOTCH1 NCID and SIRT1; leads to a epigenetic repression
CC       of selective NOTCH1-target genes. Interacts (nor via BTB domain neither
CC       acetylated) with the NuRD complex components CHD4, HDAC1, MBD3 and
CC       MTA3; the interaction with MTA3 inhibits BCL6 acetylation and is
CC       required for BCL6 transpriptional repression.
CC       {ECO:0000269|PubMed:12402037, ECO:0000269|PubMed:12504096,
CC       ECO:0000269|PubMed:12590135, ECO:0000269|PubMed:14690607,
CC       ECO:0000269|PubMed:15454082, ECO:0000269|PubMed:16142238,
CC       ECO:0000269|PubMed:17828269, ECO:0000269|PubMed:18212045,
CC       ECO:0000269|PubMed:18280243, ECO:0000269|PubMed:20385364,
CC       ECO:0000269|PubMed:22113614, ECO:0000269|PubMed:23911289}.
CC   -!- INTERACTION:
CC       P41182; Q8N9V6-2: ANKRD53; NbExp=3; IntAct=EBI-765407, EBI-13345447;
CC       P41182; Q96B67: ARRDC3; NbExp=3; IntAct=EBI-765407, EBI-2875665;
CC       P41182; Q9Y6H3: ATP23; NbExp=3; IntAct=EBI-765407, EBI-12811889;
CC       P41182; P41182: BCL6; NbExp=4; IntAct=EBI-765407, EBI-765407;
CC       P41182; A8KA13: BCL6B; NbExp=3; IntAct=EBI-765407, EBI-10174813;
CC       P41182; Q9H2G9: BLZF1; NbExp=4; IntAct=EBI-765407, EBI-2548012;
CC       P41182; Q96LM5: C4orf45; NbExp=3; IntAct=EBI-765407, EBI-12020542;
CC       P41182; Q8N865: C7orf31; NbExp=3; IntAct=EBI-765407, EBI-10174456;
CC       P41182; Q6P656: CFAP161; NbExp=3; IntAct=EBI-765407, EBI-11901329;
CC       P41182; B2RV13: CFAP97D1; NbExp=3; IntAct=EBI-765407, EBI-12870048;
CC       P41182; Q9NZN8: CNOT2; NbExp=3; IntAct=EBI-765407, EBI-743033;
CC       P41182; Q9NTM9: CUTC; NbExp=3; IntAct=EBI-765407, EBI-714918;
CC       P41182; Q86XK2: FBXO11; NbExp=9; IntAct=EBI-765407, EBI-1047804;
CC       P41182; Q08379: GOLGA2; NbExp=5; IntAct=EBI-765407, EBI-618309;
CC       P41182; P56524: HDAC4; NbExp=3; IntAct=EBI-765407, EBI-308629;
CC       P41182; Q9UKV0: HDAC9; NbExp=2; IntAct=EBI-765407, EBI-765444;
CC       P41182; Q9BVG8: KIFC3; NbExp=3; IntAct=EBI-765407, EBI-2125614;
CC       P41182; Q53G59: KLHL12; NbExp=3; IntAct=EBI-765407, EBI-740929;
CC       P41182; Q9BS75: KLHL20; NbExp=3; IntAct=EBI-765407, EBI-10693436;
CC       P41182; Q52LG2: KRTAP13-2; NbExp=3; IntAct=EBI-765407, EBI-11953846;
CC       P41182; Q8IUB9: KRTAP19-1; NbExp=3; IntAct=EBI-765407, EBI-12811111;
CC       P41182; P0CW20: LIMS4; NbExp=6; IntAct=EBI-765407, EBI-10196832;
CC       P41182; Q9BYU1: PBX4; NbExp=3; IntAct=EBI-765407, EBI-10302990;
CC       P41182; Q99471: PFDN5; NbExp=3; IntAct=EBI-765407, EBI-357275;
CC       P41182; Q8WVV4-1: POF1B; NbExp=3; IntAct=EBI-765407, EBI-11986735;
CC       P41182; Q8NI37: PPTC7; NbExp=3; IntAct=EBI-765407, EBI-9089276;
CC       P41182; P28070: PSMB4; NbExp=3; IntAct=EBI-765407, EBI-603350;
CC       P41182; Q04864-2: REL; NbExp=3; IntAct=EBI-765407, EBI-10829018;
CC       P41182; Q8IUQ4: SIAH1; NbExp=3; IntAct=EBI-765407, EBI-747107;
CC       P41182; Q8NCR6: SMRP1; NbExp=3; IntAct=EBI-765407, EBI-10269322;
CC       P41182; Q8WW24: TEKT4; NbExp=3; IntAct=EBI-765407, EBI-750487;
CC       P41182; Q08117: TLE5; NbExp=3; IntAct=EBI-765407, EBI-717810;
CC       P41182; Q12888: TP53BP1; NbExp=3; IntAct=EBI-765407, EBI-396540;
CC       P41182; Q13077: TRAF1; NbExp=5; IntAct=EBI-765407, EBI-359224;
CC       P41182; Q12933: TRAF2; NbExp=3; IntAct=EBI-765407, EBI-355744;
CC       P41182; Q96RU7: TRIB3; NbExp=4; IntAct=EBI-765407, EBI-492476;
CC       P41182; Q9BRX9: WDR83; NbExp=3; IntAct=EBI-765407, EBI-7705033;
CC       P41182; O15156: ZBTB7B; NbExp=3; IntAct=EBI-765407, EBI-740434;
CC       P41182; Q9ULU4: ZMYND8; NbExp=3; IntAct=EBI-765407, EBI-765834;
CC       P41182; O43257: ZNHIT1; NbExp=3; IntAct=EBI-765407, EBI-347522;
CC       P41182; P45481: Crebbp; Xeno; NbExp=2; IntAct=EBI-765407, EBI-296306;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:12504096,
CC       ECO:0000269|PubMed:17828269, ECO:0000269|PubMed:22113614,
CC       ECO:0000269|PubMed:23166356}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P41182-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P41182-2; Sequence=VSP_042709;
CC   -!- TISSUE SPECIFICITY: Expressed in germinal center T- and B-cells and in
CC       primary immature dendritic cells. {ECO:0000269|PubMed:10981963,
CC       ECO:0000269|PubMed:12402037, ECO:0000269|PubMed:15454082,
CC       ECO:0000269|PubMed:16142238, ECO:0000269|PubMed:16455075,
CC       ECO:0000269|PubMed:17828269, ECO:0000269|PubMed:18212045,
CC       ECO:0000269|PubMed:9649500}.
CC   -!- INDUCTION: Down-regulated during maturation of dendritic cells by
CC       selective stimuli such as bacterial lipopolysaccharides (LPS), CD40LG
CC       and zymosan. Protein levels decreases upon genotoxic stress in a
CC       dose- and time-dependent way. {ECO:0000269|PubMed:16455075,
CC       ECO:0000269|PubMed:17828269}.
CC   -!- DOMAIN: The BTB domain mediates homodimerization. Its dimer interface
CC       mediates peptide binding such as to corepressors BCOR and NCOR2
CC       (PubMed:18212045). Interaction with corepressors through the BTB domain
CC       is needed to facilitate the rapid proliferation and survival of GC B-
CC       cells but is not involved in the T(FH) formation and BCL6-mediated
CC       suppression of T(H)2 and T(H)17 differentiationrequired for GC
CC       formation (By similarity). {ECO:0000250, ECO:0000269|PubMed:18212045}.
CC   -!- PTM: Phosphorylated by MAPK1 in response to antigen receptor activation
CC       at Ser-333 and Ser-343. Phosphorylated by ATM in response to genotoxic
CC       stress. Phosphorylation induces its degradation by ubiquitin/proteasome
CC       pathway. {ECO:0000269|PubMed:17828269, ECO:0000269|PubMed:22113614,
CC       ECO:0000269|PubMed:9649500}.
CC   -!- PTM: Polyubiquitinated (PubMed:9649500, PubMed:22113614,
CC       PubMed:30190310). Polyubiquitinated by SCF(FBXO11), leading to its
CC       degradation by the proteasome (PubMed:22113614). Ubiquitinated by the
CC       SCF(FBXL17) complex, leading to its degradation by the proteasome:
CC       ubiquitination by the SCF(FBXL17) complex takes place when aberrant BTB
CC       domain dimers are formed (PubMed:30190310).
CC       {ECO:0000269|PubMed:22113614, ECO:0000269|PubMed:30190310,
CC       ECO:0000269|PubMed:9649500}.
CC   -!- PTM: Acetylated at Lys-379 by EP300 which inhibits the interaction with
CC       NuRD complex and the transcriptional repressor function. Deacetylated
CC       by HDAC- and SIR2-dependent pathways. {ECO:0000269|PubMed:12402037,
CC       ECO:0000269|PubMed:15454082}.
CC   -!- DISEASE: Note=Chromosomal aberrations involving BCL6 are a cause of B-
CC       cell non-Hodgkin lymphomas (B-cell NHL), including diffuse large B-cell
CC       lymphoma and follicular lymphoma. Approximately 40% of diffuse large B-
CC       cell lymphomas and 5 to 10% of follicular lymphomas are associated with
CC       chromosomal translocations that deregulate expression of BCL6 by
CC       juxtaposing heterologous promoters to the BCL6 coding domain
CC       (PubMed:10469447, PubMed:10753856, PubMed:12414651, PubMed:11821949).
CC       Translocation t(3;14)(q27;q32). Translocation t(3;22)(q27;q11) with
CC       immunoglobulin gene regions (PubMed:11821949). Translocation
CC       t(3;7)(q27;p12) with IKZF1 gene 5'non-coding region (PubMed:10753856).
CC       Translocation t(3;6)(q27;p21) with Histone H4 (PubMed:12414651).
CC       Translocation t(3;16)(q27;p11) with IL21R. Translocation
CC       t(3;13)(q27;q14) with LCP1 (PubMed:10469447).
CC       {ECO:0000269|PubMed:10469447, ECO:0000269|PubMed:10753856,
CC       ECO:0000269|PubMed:11821949, ECO:0000269|PubMed:12414651}.
CC   -!- DISEASE: Note=A chromosomal aberration involving BCL6 may be a cause of
CC       a form of B-cell leukemia. Translocation t(3;11)(q27;q23) with
CC       POU2AF1/OBF1.
CC   -!- DISEASE: Note=A chromosomal aberration involving BCL6 may be a cause of
CC       lymphoma. Translocation t(3;4)(q27;p11) with ARHH/TTF.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/20/BCL6";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; Z21943; CAA79937.1; -; mRNA.
DR   EMBL; U00115; AAC50054.1; -; mRNA.
DR   EMBL; S67779; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; EU139066; ABX45135.1; -; mRNA.
DR   EMBL; AC072022; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471052; EAW78140.1; -; Genomic_DNA.
DR   EMBL; CH471052; EAW78141.1; -; Genomic_DNA.
DR   EMBL; BC150184; AAI50185.1; -; mRNA.
DR   CCDS; CCDS3289.1; -. [P41182-1]
DR   CCDS; CCDS46975.1; -. [P41182-2]
DR   PIR; A48752; A48752.
DR   PIR; I52586; I52586.
DR   RefSeq; NP_001124317.1; NM_001130845.1. [P41182-1]
DR   RefSeq; NP_001128210.1; NM_001134738.1. [P41182-2]
DR   RefSeq; NP_001697.2; NM_001706.4. [P41182-1]
DR   RefSeq; XP_005247751.1; XM_005247694.3. [P41182-1]
DR   RefSeq; XP_011511364.1; XM_011513062.2. [P41182-2]
DR   PDB; 1R28; X-ray; 2.20 A; A/B=5-129.
DR   PDB; 1R29; X-ray; 1.30 A; A=5-129.
DR   PDB; 1R2B; X-ray; 2.20 A; A/B=5-129.
DR   PDB; 2EN2; NMR; -; A=598-626.
DR   PDB; 2EOS; NMR; -; A=626-654.
DR   PDB; 2LCE; NMR; -; A=540-602.
DR   PDB; 2YRM; NMR; -; A=515-544.
DR   PDB; 3BIM; X-ray; 2.60 A; A/B/C/D/E/F/G/H=5-129.
DR   PDB; 3E4U; X-ray; 2.10 A; A/B/C/D/E/F=5-129.
DR   PDB; 3LBZ; X-ray; 2.30 A; A/B=5-129.
DR   PDB; 4CP3; X-ray; 2.30 A; A/B=9-128.
DR   PDB; 4U2M; X-ray; 2.23 A; A/B/C/D=5-129.
DR   PDB; 5H7G; X-ray; 1.85 A; A/B=5-129.
DR   PDB; 5H7H; X-ray; 1.95 A; A=5-129.
DR   PDB; 5MW2; X-ray; 2.35 A; A=5-129.
DR   PDB; 5MW6; X-ray; 1.65 A; A/B=5-129.
DR   PDB; 5MWD; X-ray; 1.85 A; A=5-129.
DR   PDB; 5N1X; X-ray; 1.72 A; A=9-128, B/C=7-127, D=9-125.
DR   PDB; 5N1Z; X-ray; 1.81 A; A=6-128.
DR   PDB; 5N20; X-ray; 1.38 A; A=6-128.
DR   PDB; 5N21; X-ray; 1.58 A; A/B=7-128.
DR   PDB; 5X4M; X-ray; 1.65 A; A=5-129.
DR   PDB; 5X4N; X-ray; 1.94 A; A=5-129.
DR   PDB; 5X4O; X-ray; 2.05 A; A=5-129.
DR   PDB; 5X4P; X-ray; 2.06 A; A=5-129.
DR   PDB; 5X4Q; X-ray; 2.00 A; A=5-129.
DR   PDB; 5X9O; X-ray; 1.58 A; A=5-129.
DR   PDB; 5X9P; X-ray; 1.86 A; A=5-129.
DR   PDB; 6C3L; X-ray; 1.46 A; A/B=5-129.
DR   PDB; 6C3N; X-ray; 2.53 A; A/B=1-129.
DR   PDB; 6CQ1; X-ray; 1.70 A; A/B=1-129.
DR   PDB; 6EW6; X-ray; 1.39 A; A=6-128.
DR   PDB; 6EW7; X-ray; 1.60 A; A/B=7-128.
DR   PDB; 6EW8; X-ray; 1.84 A; A=6-129.
DR   PDB; 6TBT; X-ray; 1.63 A; A/B=6-129.
DR   PDB; 6TCJ; X-ray; 2.13 A; A/B=6-129.
DR   PDB; 6TOF; X-ray; 1.67 A; A=5-129.
DR   PDB; 6TOG; X-ray; 1.69 A; A=5-129.
DR   PDB; 6TOH; X-ray; 1.58 A; A=5-129.
DR   PDB; 6TOI; X-ray; 1.58 A; A=5-129.
DR   PDB; 6TOJ; X-ray; 1.85 A; A=5-129.
DR   PDB; 6TOK; X-ray; 1.43 A; A=5-129.
DR   PDB; 6TOL; X-ray; 1.64 A; A=5-129.
DR   PDB; 6TOM; X-ray; 1.90 A; A=5-129.
DR   PDB; 6TON; X-ray; 2.36 A; A=5-129.
DR   PDB; 6TOO; X-ray; 1.53 A; A=5-129.
DR   PDB; 6XMX; EM; 3.70 A; A/B/C/D/E/F/G/H=5-360.
DR   PDB; 6XWF; X-ray; 1.60 A; A=6-129.
DR   PDB; 6XXS; X-ray; 3.25 A; A/B/E/F=6-129.
DR   PDB; 6XYX; X-ray; 1.44 A; A/B=6-129.
DR   PDB; 6XZZ; X-ray; 1.39 A; A=6-129.
DR   PDB; 6Y17; X-ray; 1.56 A; A/B=6-129.
DR   PDB; 6ZBU; X-ray; 2.46 A; A/B/E/F/I/J=6-129.
DR   PDB; 7BDE; X-ray; 2.04 A; A=5-129.
DR   PDB; 7LWE; X-ray; 1.17 A; A=1-129.
DR   PDB; 7LWF; X-ray; 1.22 A; A=5-129.
DR   PDB; 7LWG; X-ray; 1.30 A; A/B=5-129.
DR   PDB; 7LZQ; X-ray; 1.71 A; A=1-129.
DR   PDB; 7LZR; X-ray; 1.34 A; A/B/C/D=5-129.
DR   PDB; 7LZS; X-ray; 1.49 A; A=5-129.
DR   PDB; 7OKD; X-ray; 1.94 A; A=5-129.
DR   PDB; 7OKE; X-ray; 1.48 A; A=5-129.
DR   PDB; 7OKF; X-ray; 1.60 A; A=5-129.
DR   PDB; 7OKG; X-ray; 1.32 A; A=5-129.
DR   PDB; 7OKH; X-ray; 1.52 A; A=5-129.
DR   PDB; 7OKI; X-ray; 1.61 A; A=5-129.
DR   PDB; 7OKJ; X-ray; 1.43 A; A=5-129.
DR   PDB; 7OKK; X-ray; 2.05 A; A=5-129.
DR   PDB; 7OKL; X-ray; 1.20 A; A=5-129.
DR   PDB; 7OKM; X-ray; 1.48 A; A=5-129.
DR   PDB; 7Q7R; X-ray; 1.70 A; A=5-129.
DR   PDB; 7Q7S; X-ray; 1.44 A; A=5-129.
DR   PDB; 7Q7T; X-ray; 1.46 A; A=5-129.
DR   PDB; 7Q7U; X-ray; 1.78 A; A=5-129.
DR   PDB; 7Q7V; X-ray; 1.81 A; A=5-129.
DR   PDB; 7QK0; X-ray; 1.96 A; A=5-129.
DR   PDB; 7RUW; X-ray; 1.30 A; A=5-129.
DR   PDB; 7RUX; X-ray; 1.30 A; A=5-129.
DR   PDB; 7RUY; X-ray; 1.27 A; A=5-129.
DR   PDB; 7RUZ; X-ray; 1.62 A; A=5-129.
DR   PDB; 7RV0; X-ray; 1.45 A; A=5-129.
DR   PDB; 7RV1; X-ray; 1.17 A; A=5-129.
DR   PDB; 7RV2; X-ray; 1.29 A; A=5-129.
DR   PDB; 7RV3; X-ray; 1.35 A; A=5-129.
DR   PDB; 7RV4; X-ray; 1.25 A; A=5-129.
DR   PDB; 7RV5; X-ray; 2.21 A; A=5-129.
DR   PDB; 7RV6; X-ray; 1.68 A; A=5-129.
DR   PDB; 7RV7; X-ray; 1.63 A; A=5-129.
DR   PDB; 7RV8; X-ray; 1.25 A; A=5-129.
DR   PDB; 7RV9; X-ray; 1.50 A; A=5-129.
DR   PDB; 7T0S; X-ray; 1.86 A; A/B/C=5-129.
DR   PDB; 7T0T; X-ray; 2.00 A; A/B/C/D/E/F=5-129.
DR   PDB; 7T0U; X-ray; 1.49 A; A/B/C/D=5-129.
DR   PDB; 7ZWN; X-ray; 2.05 A; A=5-129.
DR   PDB; 7ZWO; X-ray; 1.39 A; A=5-129.
DR   PDB; 7ZWP; X-ray; 1.85 A; A=5-129.
DR   PDB; 7ZWQ; X-ray; 1.65 A; A=5-129.
DR   PDB; 7ZWR; X-ray; 1.47 A; A=5-129.
DR   PDB; 7ZWS; X-ray; 1.53 A; A=5-129.
DR   PDB; 7ZWT; X-ray; 1.94 A; A=5-129.
DR   PDB; 7ZWU; X-ray; 1.56 A; A=5-129.
DR   PDB; 7ZWV; X-ray; 1.52 A; A=5-129.
DR   PDB; 7ZWW; X-ray; 1.67 A; A=5-129.
DR   PDB; 7ZWX; X-ray; 1.38 A; A=5-129.
DR   PDB; 7ZWY; X-ray; 1.65 A; A=5-129.
DR   PDB; 7ZWZ; X-ray; 1.40 A; A=5-129.
DR   PDBsum; 1R28; -.
DR   PDBsum; 1R29; -.
DR   PDBsum; 1R2B; -.
DR   PDBsum; 2EN2; -.
DR   PDBsum; 2EOS; -.
DR   PDBsum; 2LCE; -.
DR   PDBsum; 2YRM; -.
DR   PDBsum; 3BIM; -.
DR   PDBsum; 3E4U; -.
DR   PDBsum; 3LBZ; -.
DR   PDBsum; 4CP3; -.
DR   PDBsum; 4U2M; -.
DR   PDBsum; 5H7G; -.
DR   PDBsum; 5H7H; -.
DR   PDBsum; 5MW2; -.
DR   PDBsum; 5MW6; -.
DR   PDBsum; 5MWD; -.
DR   PDBsum; 5N1X; -.
DR   PDBsum; 5N1Z; -.
DR   PDBsum; 5N20; -.
DR   PDBsum; 5N21; -.
DR   PDBsum; 5X4M; -.
DR   PDBsum; 5X4N; -.
DR   PDBsum; 5X4O; -.
DR   PDBsum; 5X4P; -.
DR   PDBsum; 5X4Q; -.
DR   PDBsum; 5X9O; -.
DR   PDBsum; 5X9P; -.
DR   PDBsum; 6C3L; -.
DR   PDBsum; 6C3N; -.
DR   PDBsum; 6CQ1; -.
DR   PDBsum; 6EW6; -.
DR   PDBsum; 6EW7; -.
DR   PDBsum; 6EW8; -.
DR   PDBsum; 6TBT; -.
DR   PDBsum; 6TCJ; -.
DR   PDBsum; 6TOF; -.
DR   PDBsum; 6TOG; -.
DR   PDBsum; 6TOH; -.
DR   PDBsum; 6TOI; -.
DR   PDBsum; 6TOJ; -.
DR   PDBsum; 6TOK; -.
DR   PDBsum; 6TOL; -.
DR   PDBsum; 6TOM; -.
DR   PDBsum; 6TON; -.
DR   PDBsum; 6TOO; -.
DR   PDBsum; 6XMX; -.
DR   PDBsum; 6XWF; -.
DR   PDBsum; 6XXS; -.
DR   PDBsum; 6XYX; -.
DR   PDBsum; 6XZZ; -.
DR   PDBsum; 6Y17; -.
DR   PDBsum; 6ZBU; -.
DR   PDBsum; 7BDE; -.
DR   PDBsum; 7LWE; -.
DR   PDBsum; 7LWF; -.
DR   PDBsum; 7LWG; -.
DR   PDBsum; 7LZQ; -.
DR   PDBsum; 7LZR; -.
DR   PDBsum; 7LZS; -.
DR   PDBsum; 7OKD; -.
DR   PDBsum; 7OKE; -.
DR   PDBsum; 7OKF; -.
DR   PDBsum; 7OKG; -.
DR   PDBsum; 7OKH; -.
DR   PDBsum; 7OKI; -.
DR   PDBsum; 7OKJ; -.
DR   PDBsum; 7OKK; -.
DR   PDBsum; 7OKL; -.
DR   PDBsum; 7OKM; -.
DR   PDBsum; 7Q7R; -.
DR   PDBsum; 7Q7S; -.
DR   PDBsum; 7Q7T; -.
DR   PDBsum; 7Q7U; -.
DR   PDBsum; 7Q7V; -.
DR   PDBsum; 7QK0; -.
DR   PDBsum; 7RUW; -.
DR   PDBsum; 7RUX; -.
DR   PDBsum; 7RUY; -.
DR   PDBsum; 7RUZ; -.
DR   PDBsum; 7RV0; -.
DR   PDBsum; 7RV1; -.
DR   PDBsum; 7RV2; -.
DR   PDBsum; 7RV3; -.
DR   PDBsum; 7RV4; -.
DR   PDBsum; 7RV5; -.
DR   PDBsum; 7RV6; -.
DR   PDBsum; 7RV7; -.
DR   PDBsum; 7RV8; -.
DR   PDBsum; 7RV9; -.
DR   PDBsum; 7T0S; -.
DR   PDBsum; 7T0T; -.
DR   PDBsum; 7T0U; -.
DR   PDBsum; 7ZWN; -.
DR   PDBsum; 7ZWO; -.
DR   PDBsum; 7ZWP; -.
DR   PDBsum; 7ZWQ; -.
DR   PDBsum; 7ZWR; -.
DR   PDBsum; 7ZWS; -.
DR   PDBsum; 7ZWT; -.
DR   PDBsum; 7ZWU; -.
DR   PDBsum; 7ZWV; -.
DR   PDBsum; 7ZWW; -.
DR   PDBsum; 7ZWX; -.
DR   PDBsum; 7ZWY; -.
DR   PDBsum; 7ZWZ; -.
DR   AlphaFoldDB; P41182; -.
DR   SMR; P41182; -.
DR   BioGRID; 107076; 229.
DR   CORUM; P41182; -.
DR   DIP; DIP-2651N; -.
DR   IntAct; P41182; 125.
DR   MINT; P41182; -.
DR   STRING; 9606.ENSP00000384371; -.
DR   BindingDB; P41182; -.
DR   ChEMBL; CHEMBL4105786; -.
DR   GuidetoPHARMACOLOGY; 2957; -.
DR   iPTMnet; P41182; -.
DR   PhosphoSitePlus; P41182; -.
DR   BioMuta; BCL6; -.
DR   DMDM; 728952; -.
DR   EPD; P41182; -.
DR   jPOST; P41182; -.
DR   MassIVE; P41182; -.
DR   MaxQB; P41182; -.
DR   PaxDb; P41182; -.
DR   PeptideAtlas; P41182; -.
DR   ProteomicsDB; 55413; -. [P41182-1]
DR   ProteomicsDB; 55414; -. [P41182-2]
DR   TopDownProteomics; P41182-2; -. [P41182-2]
DR   Antibodypedia; 1434; 1259 antibodies from 50 providers.
DR   DNASU; 604; -.
DR   Ensembl; ENST00000232014.8; ENSP00000232014.4; ENSG00000113916.18. [P41182-1]
DR   Ensembl; ENST00000406870.7; ENSP00000384371.2; ENSG00000113916.18. [P41182-1]
DR   Ensembl; ENST00000450123.6; ENSP00000413122.2; ENSG00000113916.18. [P41182-2]
DR   Ensembl; ENST00000621333.4; ENSP00000479784.1; ENSG00000113916.18. [P41182-2]
DR   GeneID; 604; -.
DR   KEGG; hsa:604; -.
DR   MANE-Select; ENST00000406870.7; ENSP00000384371.2; NM_001706.5; NP_001697.2.
DR   UCSC; uc003frp.4; human. [P41182-1]
DR   AGR; HGNC:1001; -.
DR   CTD; 604; -.
DR   DisGeNET; 604; -.
DR   GeneCards; BCL6; -.
DR   HGNC; HGNC:1001; BCL6.
DR   HPA; ENSG00000113916; Tissue enhanced (skeletal).
DR   MalaCards; BCL6; -.
DR   MIM; 109565; gene.
DR   neXtProt; NX_P41182; -.
DR   OpenTargets; ENSG00000113916; -.
DR   Orphanet; 545; Follicular lymphoma.
DR   Orphanet; 480541; High grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement.
DR   Orphanet; 98839; Intravascular large B-cell lymphoma.
DR   Orphanet; 98838; Primary mediastinal large B-cell lymphoma.
DR   PharmGKB; PA25312; -.
DR   VEuPathDB; HostDB:ENSG00000113916; -.
DR   eggNOG; KOG1721; Eukaryota.
DR   GeneTree; ENSGT00940000156311; -.
DR   HOGENOM; CLU_024196_1_0_1; -.
DR   InParanoid; P41182; -.
DR   OMA; DARMPMA; -.
DR   OrthoDB; 5352496at2759; -.
DR   PhylomeDB; P41182; -.
DR   TreeFam; TF330912; -.
DR   PathwayCommons; P41182; -.
DR   Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling.
DR   Reactome; R-HSA-6803205; TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain.
DR   Reactome; R-HSA-9614657; FOXO-mediated transcription of cell death genes.
DR   SignaLink; P41182; -.
DR   SIGNOR; P41182; -.
DR   BioGRID-ORCS; 604; 47 hits in 1225 CRISPR screens.
DR   ChiTaRS; BCL6; human.
DR   EvolutionaryTrace; P41182; -.
DR   GeneWiki; BCL6; -.
DR   GenomeRNAi; 604; -.
DR   Pharos; P41182; Tchem.
DR   PRO; PR:P41182; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; P41182; protein.
DR   Bgee; ENSG00000113916; Expressed in gastrocnemius and 209 other tissues.
DR   ExpressionAtlas; P41182; baseline and differential.
DR   Genevisible; P41182; HS.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:HPA.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0042382; C:paraspeckles; IDA:UniProtKB.
DR   GO; GO:0003682; F:chromatin binding; IDA:MGI.
DR   GO; GO:0031490; F:chromatin DNA binding; IEA:Ensembl.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IMP:UniProtKB.
DR   GO; GO:0140297; F:DNA-binding transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0001227; F:DNA-binding transcription repressor activity, RNA polymerase II-specific; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0001161; F:intronic transcription regulatory region sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:1990837; F:sequence-specific double-stranded DNA binding; IDA:ARUK-UCL.
DR   GO; GO:0001222; F:transcription corepressor binding; IPI:UniProtKB.
DR   GO; GO:0030036; P:actin cytoskeleton organization; IEA:Ensembl.
DR   GO; GO:0042100; P:B cell proliferation; IEA:Ensembl.
DR   GO; GO:0000902; P:cell morphogenesis; IEA:Ensembl.
DR   GO; GO:0048870; P:cell motility; IEA:Ensembl.
DR   GO; GO:0007160; P:cell-matrix adhesion; IEA:Ensembl.
DR   GO; GO:0006974; P:DNA damage response; IDA:UniProtKB.
DR   GO; GO:0048821; P:erythrocyte development; IEA:Ensembl.
DR   GO; GO:0002467; P:germinal center formation; IEA:Ensembl.
DR   GO; GO:0031507; P:heterochromatin formation; IEA:Ensembl.
DR   GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW.
DR   GO; GO:0048289; P:isotype switching to IgE isotypes; IEA:Ensembl.
DR   GO; GO:0002903; P:negative regulation of B cell apoptotic process; NAS:UniProtKB.
DR   GO; GO:0030308; P:negative regulation of cell growth; IDA:UniProtKB.
DR   GO; GO:0001953; P:negative regulation of cell-matrix adhesion; IEA:Ensembl.
DR   GO; GO:2000773; P:negative regulation of cellular senescence; IEA:Ensembl.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; IMP:UniProtKB.
DR   GO; GO:0048294; P:negative regulation of isotype switching to IgE isotypes; IEA:Ensembl.
DR   GO; GO:0070664; P:negative regulation of leukocyte proliferation; IEA:Ensembl.
DR   GO; GO:0032764; P:negative regulation of mast cell cytokine production; IEA:Ensembl.
DR   GO; GO:1903464; P:negative regulation of mitotic cell cycle DNA replication; NAS:UniProtKB.
DR   GO; GO:0045746; P:negative regulation of Notch signaling pathway; IEA:Ensembl.
DR   GO; GO:1900099; P:negative regulation of plasma cell differentiation; IEA:Ensembl.
DR   GO; GO:0035024; P:negative regulation of Rho protein signal transduction; IEA:Ensembl.
DR   GO; GO:0045629; P:negative regulation of T-helper 2 cell differentiation; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0002317; P:plasma cell differentiation; IEA:Ensembl.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0030890; P:positive regulation of B cell proliferation; IEA:Ensembl.
DR   GO; GO:0045666; P:positive regulation of neuron differentiation; IEA:Ensembl.
DR   GO; GO:0045591; P:positive regulation of regulatory T cell differentiation; IMP:ARUK-UCL.
DR   GO; GO:0008104; P:protein localization; IEA:Ensembl.
DR   GO; GO:0021859; P:pyramidal neuron differentiation; IEA:Ensembl.
DR   GO; GO:0042127; P:regulation of cell population proliferation; IBA:GO_Central.
DR   GO; GO:0001817; P:regulation of cytokine production; IBA:GO_Central.
DR   GO; GO:0002634; P:regulation of germinal center formation; NAS:UniProtKB.
DR   GO; GO:0043087; P:regulation of GTPase activity; IEA:Ensembl.
DR   GO; GO:0050776; P:regulation of immune response; NAS:UniProtKB.
DR   GO; GO:0002682; P:regulation of immune system process; IBA:GO_Central.
DR   GO; GO:0050727; P:regulation of inflammatory response; IBA:GO_Central.
DR   GO; GO:0043380; P:regulation of memory T cell differentiation; IEA:Ensembl.
DR   GO; GO:0042129; P:regulation of T cell proliferation; IEA:Ensembl.
DR   GO; GO:0007266; P:Rho protein signal transduction; IEA:Ensembl.
DR   GO; GO:0007283; P:spermatogenesis; IEA:Ensembl.
DR   GO; GO:0045064; P:T-helper 2 cell differentiation; IEA:Ensembl.
DR   GO; GO:0006366; P:transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0042092; P:type 2 immune response; IBA:GO_Central.
DR   CDD; cd18331; BTB_POZ_ZBTB27_BCL6; 1.
DR   Gene3D; 3.30.160.60; Classic Zinc Finger; 6.
DR   IDEAL; IID00372; -.
DR   InterPro; IPR000210; BTB/POZ_dom.
DR   InterPro; IPR011333; SKP1/BTB/POZ_sf.
DR   InterPro; IPR036236; Znf_C2H2_sf.
DR   InterPro; IPR013087; Znf_C2H2_type.
DR   PANTHER; PTHR24399:SF29; B-CELL LYMPHOMA 6 PROTEIN; 1.
DR   PANTHER; PTHR24399; ZINC FINGER AND BTB DOMAIN-CONTAINING; 1.
DR   Pfam; PF00651; BTB; 1.
DR   Pfam; PF00096; zf-C2H2; 3.
DR   SMART; SM00225; BTB; 1.
DR   SMART; SM00355; ZnF_C2H2; 6.
DR   SUPFAM; SSF57667; beta-beta-alpha zinc fingers; 3.
DR   SUPFAM; SSF54695; POZ domain; 1.
DR   PROSITE; PS50097; BTB; 1.
DR   PROSITE; PS00028; ZINC_FINGER_C2H2_1; 6.
DR   PROSITE; PS50157; ZINC_FINGER_C2H2_2; 6.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Alternative splicing;
KW   Chromosomal rearrangement; DNA-binding; Immunity; Inflammatory response;
KW   Metal-binding; Nucleus; Phosphoprotein; Proto-oncogene; Reference proteome;
KW   Repeat; Repressor; Transcription; Transcription regulation;
KW   Ubl conjugation; Zinc; Zinc-finger.
FT   CHAIN           1..706
FT                   /note="B-cell lymphoma 6 protein"
FT                   /id="PRO_0000047098"
FT   DOMAIN          32..99
FT                   /note="BTB"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00037"
FT   ZN_FING         518..541
FT                   /note="C2H2-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         546..568
FT                   /note="C2H2-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         574..596
FT                   /note="C2H2-type 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         602..624
FT                   /note="C2H2-type 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         630..652
FT                   /note="C2H2-type 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         658..681
FT                   /note="C2H2-type 6"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   REGION          317..349
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          376..379
FT                   /note="Required for interaction with NuRD complex and for
FT                   transcriptional repressor activity"
FT   REGION          407..467
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        326..349
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        425..467
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         333
FT                   /note="Phosphoserine; by MAPK1"
FT                   /evidence="ECO:0000269|PubMed:9649500,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         343
FT                   /note="Phosphoserine; by MAPK1"
FT                   /evidence="ECO:0000269|PubMed:9649500"
FT   MOD_RES         361
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P41183"
FT   MOD_RES         379
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:12402037"
FT   MOD_RES         404
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P41183"
FT   VAR_SEQ         514..569
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|Ref.5"
FT                   /id="VSP_042709"
FT   VARIANT         252
FT                   /note="N -> S (in dbSNP:rs34463990)"
FT                   /id="VAR_052709"
FT   VARIANT         493
FT                   /note="A -> T (in dbSNP:rs2229362)"
FT                   /id="VAR_019970"
FT   VARIANT         676
FT                   /note="H -> Y (in dbSNP:rs1056936)"
FT                   /id="VAR_014825"
FT   MUTAGEN         21
FT                   /note="N->K: Abolishes interaction with NCOR2 and HDAC2, no
FT                   effect on interaction with CTBP1 and transcriptional
FT                   autoinhibition; when associated with A-116 and
FT                   376-Q--Q-379."
FT                   /evidence="ECO:0000269|PubMed:18212045"
FT   MUTAGEN         59
FT                   /note="S->A: Abolished ubiquitination by the SCF(FBXL17)
FT                   complex."
FT                   /evidence="ECO:0000269|PubMed:30190310"
FT   MUTAGEN         116
FT                   /note="H->A: Abolishes interaction with NCOR2 and HDAC2, no
FT                   effect on interaction with CTBP1 and transcriptional
FT                   autoinhibition; when associated with K-21 and
FT                   376-Q--Q-379."
FT                   /evidence="ECO:0000269|PubMed:18212045"
FT   MUTAGEN         190
FT                   /note="T->A: No effect on interaction with PIN1."
FT                   /evidence="ECO:0000269|PubMed:17828269"
FT   MUTAGEN         250
FT                   /note="S->A: No effect on interaction with PIN1."
FT                   /evidence="ECO:0000269|PubMed:17828269"
FT   MUTAGEN         260
FT                   /note="S->A: Strongly reduces interaction with PIN1."
FT                   /evidence="ECO:0000269|PubMed:17828269"
FT   MUTAGEN         333
FT                   /note="S->A: Decrease in phosphorylation by MAPK1."
FT                   /evidence="ECO:0000269|PubMed:9649500"
FT   MUTAGEN         343
FT                   /note="S->A: Decrease in phosphorylation by MAPK1."
FT                   /evidence="ECO:0000269|PubMed:9649500"
FT   MUTAGEN         376..379
FT                   /note="KKYK->QQYQ: Abolishes interaction with HDAC2 and
FT                   MTA3 as well as transcriptional repressor and transforming
FT                   activities. Abolishes interaction with NCOR2 and HDAC2, no
FT                   effect on interaction with CTBP1 and transcriptional
FT                   autoinhibition; when associated with K-21 and A-116."
FT                   /evidence="ECO:0000269|PubMed:15454082,
FT                   ECO:0000269|PubMed:18212045"
FT   MUTAGEN         376
FT                   /note="K->R: No effect on acetylation."
FT                   /evidence="ECO:0000269|PubMed:12402037"
FT   MUTAGEN         377
FT                   /note="K->R: No effect on acetylation."
FT                   /evidence="ECO:0000269|PubMed:12402037"
FT   MUTAGEN         379
FT                   /note="K->R: Abolishes acetylation. No effect on
FT                   interaction with MTA3, NCOR1 and NCOR2."
FT                   /evidence="ECO:0000269|PubMed:12402037,
FT                   ECO:0000269|PubMed:15454082"
FT   MUTAGEN         520..523
FT                   /note="CNEC->GNEG: No effect on DNA-binding, nuclear
FT                   localization, transcriptional repression activity and
FT                   interaction with HDAC5."
FT                   /evidence="ECO:0000269|PubMed:12504096"
FT   MUTAGEN         548..551
FT                   /note="CDRC->GDRG: No effect on DNA-binding, nuclear
FT                   localization, transcriptional repression activity and
FT                   interaction with HDAC5."
FT                   /evidence="ECO:0000269|PubMed:12504096"
FT   MUTAGEN         576..579
FT                   /note="CNIC->GNIG: Abolishes DNA-binding and
FT                   transcriptional repression activity, no effect on nuclear
FT                   localization and interaction with HDAC5."
FT                   /evidence="ECO:0000269|PubMed:12504096"
FT   MUTAGEN         604..607
FT                   /note="CETC->GETG: Abolishes DNA-binding and
FT                   transcriptional repression activity, perturbs nuclear
FT                   localization. No effect on interaction with HDAC5."
FT                   /evidence="ECO:0000269|PubMed:12504096"
FT   MUTAGEN         632..635
FT                   /note="CEIC->GEIG: Abolishes DNA-binding and
FT                   transcriptional repression activity, no effect on nuclear
FT                   localization and interaction with HDAC5."
FT                   /evidence="ECO:0000269|PubMed:12504096"
FT   MUTAGEN         660..663
FT                   /note="CEKC->GEKG: Abolishes DNA-binding and
FT                   transcriptional repression activity, perturbs nuclear
FT                   localization. No effect on interaction with HDAC5."
FT                   /evidence="ECO:0000269|PubMed:12504096"
FT   CONFLICT        347
FT                   /note="S -> A (in Ref. 2; AAC50054)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        393
FT                   /note="E -> G (in Ref. 2; AAC50054)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        498
FT                   /note="P -> A (in Ref. 2; AAC50054)"
FT                   /evidence="ECO:0000305"
FT   STRAND          7..10
FT                   /evidence="ECO:0007829|PDB:7LZR"
FT   HELIX           14..27
FT                   /evidence="ECO:0007829|PDB:7OKL"
FT   TURN            29..31
FT                   /evidence="ECO:0007829|PDB:3E4U"
FT   STRAND          34..38
FT                   /evidence="ECO:0007829|PDB:7OKL"
FT   STRAND          41..45
FT                   /evidence="ECO:0007829|PDB:7OKL"
FT   HELIX           47..53
FT                   /evidence="ECO:0007829|PDB:7OKL"
FT   HELIX           55..62
FT                   /evidence="ECO:0007829|PDB:7OKL"
FT   HELIX           66..68
FT                   /evidence="ECO:0007829|PDB:7OKL"
FT   STRAND          70..73
FT                   /evidence="ECO:0007829|PDB:7OKL"
FT   HELIX           80..92
FT                   /evidence="ECO:0007829|PDB:7OKL"
FT   STRAND          93..95
FT                   /evidence="ECO:0007829|PDB:7LZR"
FT   TURN            99..101
FT                   /evidence="ECO:0007829|PDB:7OKL"
FT   HELIX           102..112
FT                   /evidence="ECO:0007829|PDB:7OKL"
FT   HELIX           115..127
FT                   /evidence="ECO:0007829|PDB:7OKL"
FT   STRAND          521..523
FT                   /evidence="ECO:0007829|PDB:2YRM"
FT   STRAND          527..529
FT                   /evidence="ECO:0007829|PDB:2YRM"
FT   HELIX           530..540
FT                   /evidence="ECO:0007829|PDB:2YRM"
FT   HELIX           558..568
FT                   /evidence="ECO:0007829|PDB:2LCE"
FT   STRAND          573..575
FT                   /evidence="ECO:0007829|PDB:2LCE"
FT   TURN            577..579
FT                   /evidence="ECO:0007829|PDB:2LCE"
FT   STRAND          582..584
FT                   /evidence="ECO:0007829|PDB:2LCE"
FT   HELIX           586..596
FT                   /evidence="ECO:0007829|PDB:2LCE"
FT   STRAND          601..603
FT                   /evidence="ECO:0007829|PDB:2EN2"
FT   TURN            605..607
FT                   /evidence="ECO:0007829|PDB:2EN2"
FT   STRAND          610..613
FT                   /evidence="ECO:0007829|PDB:2EN2"
FT   HELIX           614..620
FT                   /evidence="ECO:0007829|PDB:2EN2"
FT   HELIX           622..625
FT                   /evidence="ECO:0007829|PDB:2EN2"
FT   STRAND          633..635
FT                   /evidence="ECO:0007829|PDB:2EOS"
FT   STRAND          639..641
FT                   /evidence="ECO:0007829|PDB:2EOS"
FT   HELIX           642..648
FT                   /evidence="ECO:0007829|PDB:2EOS"
FT   TURN            649..652
FT                   /evidence="ECO:0007829|PDB:2EOS"
SQ   SEQUENCE   706 AA;  78846 MW;  E38D83C213DAE2D0 CRC64;
     MASPADSCIQ FTRHASDVLL NLNRLRSRDI LTDVVIVVSR EQFRAHKTVL MACSGLFYSI
     FTDQLKCNLS VINLDPEINP EGFCILLDFM YTSRLNLREG NIMAVMATAM YLQMEHVVDT
     CRKFIKASEA EMVSAIKPPR EEFLNSRMLM PQDIMAYRGR EVVENNLPLR SAPGCESRAF
     APSLYSGLST PPASYSMYSH LPVSSLLFSD EEFRDVRMPV ANPFPKERAL PCDSARPVPG
     EYSRPTLEVS PNVCHSNIYS PKETIPEEAR SDMHYSVAEG LKPAAPSARN APYFPCDKAS
     KEEERPSSED EIALHFEPPN APLNRKGLVS PQSPQKSDCQ PNSPTESCSS KNACILQASG
     SPPAKSPTDP KACNWKKYKF IVLNSLNQNA KPEGPEQAEL GRLSPRAYTA PPACQPPMEP
     ENLDLQSPTK LSASGEDSTI PQASRLNNIV NRSMTGSPRS SSESHSPLYM HPPKCTSCGS
     QSPQHAEMCL HTAGPTFPEE MGETQSEYSD SSCENGAFFC NECDCRFSEE ASLKRHTLQT
     HSDKPYKCDR CQASFRYKGN LASHKTVHTG EKPYRCNICG AQFNRPANLK THTRIHSGEK
     PYKCETCGAR FVQVAHLRAH VLIHTGEKPY PCEICGTRFR HLQTLKSHLR IHTGEKPYHC
     EKCNLHFRHK SQLRLHLRQK HGAITNTKVQ YRVSATDLPP ELPKAC
//
